<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Rizzo, Toni</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Lublin, Fred D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Controversies in Multiple Sclerosis Therapy</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-06-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-20</style></pages><abstract><style  face="normal" font="default" size="100%">Considerable progress has been made in multiple sclerosis (MS) therapy in the 20 years since the first successful trial. Although several agents are now available for treating patients with MS, many issues remain regarding treatment of individual patients. This article discusses initiating MS therapy, and addressed the issues of switching and escalating therapy and of discontinuing therapy.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>